1155: Treatment and degree of control of asthma in primary care. ASMADUAL Study

Conference: 
Author(s): 
V. Lopez Marina1, P. Rubinstein Aguñín2, P. Gonzales Flores3, A. Pedro Pijoan4, J. Seuba5, N. Perallons Solans6, M. Mourelo Cejeiro7, A. Brau Tarrida8, M. De la Poza9, ASMADUAL GROUP2
1 Instituto Catalán de la Salud, ABS Piera, Barcelona, Spain; 2 Pneumologia, Capio Hospital General de Cataluña, Barcelona, Spain; 3 Instituto Catalán de la Salud, ABS La Farigola, Barcelona, Spain; 4 Instituto Catalán de la Salud, ABS Gaudí Sagrada Familia, Barcelona, Spain; 5 Medicina, Centre Mèdic Casteldefells, Barcelona, Spain; 6 Instituto Catalán de la Salud, ABS Polinya, Barcelona, Spain; 7 Instituto Catalán de la Salud, ABS Gòtic, Barcelona, Spain; 8 Instituto catalán de la Salud, ABS La Mina, Barcelona, Spain; 9 Instituto Catalán de la Salud, ABS Carles Ribas, Barcelona, Spain
Text: 
Objective: To describe the pharmacological treatment, adverse effects and degree of control of asthmatics.
Methodology: Descriptive, cross-sectional study, multicentre across Catalonia; 55 physicians (family, Allergists, pulmonologists and internists) from primary care Centres that became a self-administered survey their asthmatic in February to April, 2012. Variables: sex; age; smoking; treatments; adverse effects (AE); degree by the Asthma Control Test and control (ACT≤19 insufficient control, and > 19 good control (GC)). Statistics: mean (X), standard deviation (SD), percentages, T-Student independent and test exactly of Fisher.
Results: Asthmatic 578, 70% women and age (X±DE) 47, 3±17, 5 years. 12.8% smoke. Treatments: 89% takes any treatment; salbutamol 48%, budesonide/formoterol 28%, 18% budesonide, fluticasone/salmeterol 17%, 13% montelukast, etc; pAdverse effects: 14.1% had AE; tachycardia 35.5%, neuromuscular 47%, oropharyngeal 21%, p19 (pConclusions: Asthmatics are middle-aged and it hurts them tobacco.
90% takes drugs (inhalers), 14% showing adverse effects.
A 68.5% regard good control perception, but according to the ACT only 53.7% presents sufficient control, with involvement by more than 60% of patients with insufficient control.

Disclosure: No conflict of interest declared